Professor Wu Yilong: Lung Cancer and Targeted Therapy Specialist
Professor Wu Yilong is a senior thoracic oncologist, professor, and clinical researcher at Guangdong Provincial People’s Hospital in Guangzhou. He is internationally recognized for work in lung cancer precision medicine, EGFR-mutated non-small cell lung cancer, targeted therapy, postoperative treatment, drug resistance, and clinical-trial development.
Clinical and Academic Focus
- non-small cell lung cancer;
- EGFR-mutated lung cancer;
- ALK, ROS1, RET, MET, BRAF, KRAS, HER2, and other driver alterations;
- targeted therapy and resistance;
- adjuvant and neoadjuvant treatment;
- immunotherapy;
- brain metastases;
- multidisciplinary thoracic oncology; and
- clinical-trial evaluation.
Molecular Diagnosis
Lung cancer treatment increasingly depends on molecular classification. For advanced non-squamous non-small cell lung cancer, broad testing may identify an alteration with an approved targeted medicine or a relevant clinical trial.
Tissue is generally preferred because it confirms pathology and supports comprehensive testing. Blood-based liquid biopsy can help when tissue is limited or resistance develops, but a negative blood result may require tissue testing.
EGFR-Mutated Lung Cancer
EGFR alterations are common among Asian patients with lung adenocarcinoma, including people who have never smoked. EGFR tyrosine kinase inhibitors can produce substantial responses and may control disease in the brain.
The exact mutation matters. Common sensitizing mutations, uncommon variants, and exon 20 insertions can require different strategies. Treatment sequence should consider stage, symptoms, brain involvement, previous therapy, and medicine availability.
Targeted Therapy Resistance
Most advanced cancers eventually develop resistance to targeted therapy. Causes can include a new mutation in the original pathway, activation of another pathway, pathological transformation, or growth of resistant tumor populations.
Repeat tissue biopsy, liquid biopsy, or both may help define the mechanism. Options can include another targeted medicine, chemotherapy, local treatment to limited progressing sites, or a clinical trial.
Treatment Before and After Surgery
Selected patients with resectable lung cancer may receive systemic treatment before surgery or additional treatment afterward. Decisions depend on stage, pathology, driver mutations, surgical margins, lymph nodes, and treatment response.
Professor Wu has contributed to influential research on postoperative targeted therapy. Trial results should be applied according to the patient’s stage, mutation, surgical outcome, and current evidence.
Immunotherapy
Immunotherapy may be used alone or with chemotherapy for selected lung cancers. Patients with strong actionable driver alterations often require a different treatment sequence, even when PD-L1 is elevated.
Immune-related side effects can affect the lungs, liver, bowel, endocrine glands, skin, heart, and nervous system. New breathing difficulty, diarrhea, jaundice, severe fatigue, chest pain, or weakness requires prompt medical assessment.
Brain Metastases
Treatment can include a brain-penetrating targeted medicine, stereotactic radiosurgery, surgery, whole-brain radiotherapy, systemic therapy, or a combination. The plan depends on symptoms, lesion size and number, molecular findings, and disease outside the brain.
Who May Consider a Consultation?
- patients with newly diagnosed advanced non-small cell lung cancer;
- patients with an EGFR, ALK, ROS1, RET, MET, KRAS, BRAF, or HER2 alteration;
- patients whose cancer progressed after targeted therapy;
- patients needing review of tissue or liquid-biopsy results;
- patients deciding on treatment before or after surgery;
- patients with brain metastases;
- patients with conflicting recommendations about immunotherapy; or
- patients assessing clinical-trial options.
Medical Records to Prepare
- a concise medical summary and exact treatment timeline;
- chest CT, PET-CT, brain MRI, and other imaging in original DICOM format;
- pathology reports, slides, and paraffin blocks;
- complete molecular, liquid-biopsy, and PD-L1 reports;
- operative and radiotherapy records;
- every systemic treatment with dates, doses, response, and toxicity;
- recent blood count, liver and kidney function, and cardiac assessments;
- current symptoms and performance status; and
- a clear list of treatment priorities and questions.
Planning an International Consultation
Before travel, patients should confirm whether imaging, pathology, and molecular results can be reviewed. Remote medical-record review requires physician authorization. Final treatment and clinical-trial eligibility require complete specialist assessment.
How CMCS Can Assist
CMCS – China Medical Concierge Shanghai is an independent medical concierge and health management company, not a hospital. We assist international patients with organizing and translating oncology records, identifying an appropriate specialist, requesting appointment availability, arranging interpretation, and planning medical travel in China.
Access to Professor Wu, remote review, a particular medicine, or a clinical trial is subject to doctor and hospital approval. CMCS does not guarantee appointments, treatment eligibility, trial enrollment, or clinical outcomes.
- Email: contract@medicalsh.com
- WhatsApp: Contact us on WhatsApp
- Website: www.medicalsh.com
Important Note
Doctor roles, biomarker requirements, medicine approvals, trial availability, and appointment arrangements may change. This profile is for general information only and does not replace assessment by a qualified thoracic oncology team.
0 Kommentare